<SEC-DOCUMENT>0001140361-20-020303.txt : 20200914
<SEC-HEADER>0001140361-20-020303.hdr.sgml : 20200914
<ACCEPTANCE-DATETIME>20200914073604
ACCESSION NUMBER:		0001140361-20-020303
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200914
FILED AS OF DATE:		20200914
DATE AS OF CHANGE:		20200914

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InflaRx N.V.
		CENTRAL INDEX KEY:			0001708688
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38283
		FILM NUMBER:		201172288

	BUSINESS ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745
		BUSINESS PHONE:		49 3641 508180

	MAIL ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Fireman B.V.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>brhc10015075_6k.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using EDGARfilings PROfile 7.1.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
  <div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-size: 12px; font-weight: bold;">Washington, D.C. 20549</div>
    <div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 30%; color: #000000; text-align: center;"></div>
      <div><br>
      </div>
    </div>
    <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM 6-K</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div>
      <div>
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 30%; color: #000000; text-align: center;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
    <div style="text-align: center; font-weight: bold;">PURSUANT TO RULE 13A-16 OR 15D-16 UNDER</div>
    <div style="text-align: center; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">For the month of September 2020</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Commission File Number: 001-38283</div>
    <div>&#160;</div>
    <div>
      <div>
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 30%; color: #000000; text-align: center;"></div>
    </div>
    <div>&#160;</div>
    <div style="text-align: center; font-size: 24pt; font-weight: bold;">InflaRx N.V.</div>
    <div style="text-align: center; color: rgb(0, 0, 0);">(Translation of registrant's name into English)</div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 30%; color: #000000; text-align: center;"></div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">Winzerlaer Str. 2</div>
    <div style="text-align: center; font-weight: bold;">07745 Jena, Germany</div>
    <div style="text-align: center;">(Address of principal executive office)</div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 30%; color: #000000; text-align: center;"></div>
    <div>&#160;</div>
    <div>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div>&#160;</div>
    <div>Form 20-F &#9746;&#160;&#160; Form 40-F &#9744;</div>
    <div>&#160;</div>
    <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
    <div>&#160;</div>
    <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
    <div>&#160;</div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">INFLARX N.V.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">On September 14, 2020, InflaRx N.V. issued a press release. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%3%%%-->
    <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
    <div>&#160;</div>
    <div>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z3d3960c4b26945728f7b0ac8f0b39ede">

        <tr>
          <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align: top;">
            <div style="font-weight: bold;">INFLARX N.V.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 50%; vertical-align: top; padding-bottom: 2px;">
            <div>Date: September 14, 2020</div>
          </td>
          <td style="width: 2%; vertical-align: top; padding-bottom: 2px;">By:</td>
          <td style="width: 48%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Niels Riedemann</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">
            <div>Name:</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div>Niels Riedemann</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">
            <div>Title:</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div>Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z8cc70557295642d0a810ced4b003b96b">

        <tr>
          <td style="width: 10%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="font-weight: bold;">Exhibit No.</div>
            </div>
          </td>
          <td style="width: 1%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 89%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="font-weight: bold;">Description</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="brhc10015075_ex99-1.htm">99.1</a></div>
          </td>
          <td style="width: 1%; vertical-align: top;">&#160;</td>
          <td style="width: 89%; vertical-align: bottom;">
            <div>Press Release, dated September 14, 2020</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font> </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc10015075_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using EDGARfilings PROfile 7.1.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
    </div>
    <div> <br>
    </div>
    <div> <img src="image00004.jpg"></div>
    <div>&#160;<br>
    </div>
    <div style="text-align: center; margin-left: 45.35pt;">InflaRx Announces Initiation of Phase III Part of Phase II/III Clinical Trial with IFX-1 in Severe COVID-19 Induced Pneumonia</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc6c71ae242dc4c7497fe57a2b140156c">

        <tr>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>First site initiated for enrollment in the Netherlands</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7f068dae4fde4b5994c0fd1b6f9b540c">

        <tr>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Regulatory approval granted to start trial in Germany</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8eb39cd55e7b45a8b517fdd56890a73d">

        <tr>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Additional sites to be added in the US, EU and other regions</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8949dc85f7d74d1fa32114164414622c">

        <tr>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Encouraging Phase II data accepted for publication in The Lancet Rheumatology</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.9pt;"><font style="font-weight: bold;">Jena, Germany, 14 September 2020 </font>&#8211; InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting
      the complement system, announced today the start of the global Phase III part of its Phase II/III trial with IFX-1 in severe COVID-19 induced pneumonia with the initiation of the first clinical site in the Netherlands. In parallel, the German
      regulatory authority, the Paul-Ehrlich-Institut (PEI), has approved the Phase III clinical trial in Germany.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.9pt;">The randomized, double-blinded and placebo - controlled Phase III part of the Phase II/III trial plans to enroll approximately 360 early intubated, critically ill patients with COVID-19 induced
      pneumonia across sites in the US, EU, South America and other regions. Patients will be randomized 1:1 to receive either IFX-1 or placebo; all patients will receive standard of care. The primary endpoint will be 28-day all-cause mortality; key
      secondary endpoints will include assessment of organ support and disease improvement. An interim analysis is planned after enrollment of 180 patients, with a potential for an early stop for efficacy or futility.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.9pt;">Dr. Korinna Pilz, Global Head of Clinical R&amp;D at InflaRx, noted: &#8220;Encouraged by our initial Phase II results, we are now rolling out the international Phase III part of the trial. Our team is
      driven by the prospect of adding to the global efforts in the fight against this pandemic and by advancing the development of a potential therapeutic for the sickest COVID-19 patients.&#8221;</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.9pt;">The data from the Phase II part of the study, which evaluated IFX-1 treatment plus best supportive care and best supportive care alone in 30 patients, have been accepted for publication in the
      peer-reviewed journal, The Lancet Rheumatology.</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; margin-right: 3.7pt;">
      <div> <img src="image00004.jpg">
        <div><br>
        </div>
      </div>
      Dr. Alexander Vlaar, the principal investigator of the study from Amsterdam University, Department of Intensive Care Medicine, commented: &#8220;We are very pleased that a distinguished, peer-reviewed journal has recognized the significance of the Phase II
      data for patients with severe COVID-19 induced pneumonia. The results demonstrate promising early efficacy signals, including lower mortality and organ dysfunction rates, and suggest that C5a inhibition might be beneficial in critically ill COVID-19
      patients. However, these effects need to be confirmed in the large, well-powered Phase III part of the trial.&#8221;</div>
    <div>&#160;</div>
    <div style="text-align: justify;">IFX-1, which has recently been granted the International Nonproprietary Name (INN), vilobelimab, currently has additional ongoing Phase II studies in ANCA-associated vasculitis and Pyoderma Gangraenosum and has
      completed Phase IIb development in Hidradenitis Suppurativa, for which a Phase III clinical development strategy is currently being developed.</div>
    <div>&#160;</div>
    <div style="text-align: justify; font-weight: bold;">About IFX-1:</div>
    <div>&#160;</div>
    <div style="text-align: justify;">IFX-1 is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.
      Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. IFX-1 has been demonstrated to control the inflammatory response driven
      tissue and organ damage by specifically blocking C5a as a key &#8220;amplifier&#8221; of this response in pre-clinical studies. IFX-1 is believed to be the first monoclonal anti-C5a antibody introduced into clinical development. Approximately 300 people have
      been treated with IFX-1 in clinical trials, and the antibody has been shown to be well tolerated. IFX-1 is currently being developed for various indications, including Hidradenitis Suppurativa, ANCA-associated vasculitis, Pyoderma Gangraenosum and
      COVID-19 pneumonia.</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; font-weight: bold;">
      <div> <img src="image00004.jpg">
        <div><br>
        </div>
      </div>
      About InflaRx N.V.:</div>
    <div>&#160;</div>
    <div style="text-align: justify;">InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a
      is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann
      Arbor, MI, USA. For further information please visit <u>www.inflarx.com</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; font-weight: bold;">Contacts:</div>
    <div>&#160;</div>
    <div style="text-align: justify; font-weight: bold;">InflaRx N.V.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">Jordan Zwick &#8211; Global Head of Business Development &amp; Corporate Strategy</div>
    <div style="text-align: justify;">Email: jordan.zwick[at]inflarx.de</div>
    <div style="text-align: justify;">Tel: +1 917-338-6523</div>
    <div>&#160;</div>
    <div style="text-align: justify; font-weight: bold;">MC Services AG</div>
    <div>&#160;</div>
    <div style="text-align: justify;">Katja Arnold, Laurie Doyle, Andreas Jungfer</div>
    <div style="text-align: justify;">Email: inflarx[at]mc-services.eu</div>
    <div style="text-align: justify;">Europe: +49 89-210 2280</div>
    <div style="text-align: justify;">US: +1-339-832-0752</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify;">
      <div> <img src="image00004.jpg">
        <div><br>
        </div>
      </div>
      FORWARD-LOOKING STATEMENTS</div>
    <div>&#160;</div>
    <div style="text-align: justify;">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221;
      &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; and similar expressions. Forward-looking statements appear in a number of places throughout this release and may
      include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials; the impact of the COVID-19 pandemic on
      the Company; the timing and our ability to commence and conduct clinical trials; potential results from current or potential future collaborations; our ability to make regulatory filings, obtain positive guidance from regulators, and obtain and
      maintain regulatory approvals for our product candidates; our intellectual property position; our ability to develop commercial functions; expectations regarding clinical trial data; our results of operations, cash needs, financial condition,
      liquidity, prospects, future transactions, growth and strategies; the industry in which we operate; the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading &#8220;Risk Factors&#8221; in InflaRx&#8217;s
      periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results,
      performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue
      reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.</div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: justify;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00004.jpg
<TEXT>
begin 644 image00004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  ] *T# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZIH8A02Q
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MU#6+:8-;Q6LLRR8(^ZI]?<5XCXFM+>QU^]M;/=Y$,A1=QR>.#^N:Z[XO7/\
MPC_[/U[&.))K6*VQZF1@&_0M3 ^0/"M@VO>,-*L7RQO;V.-_HSC)_(FOT;48
M4 =!Q7YV?#WQ##X4\9:9KEQ:->I92&00!]FX[2!S@]"<].U>R>,/VE]0U/1Y
MK/P_HPTNXF4H;J2X\UD!_N@* #[G-#&SS+XWW=I>_%;Q)-IX3R/M17*=&90
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MUL444 8]_P"&M(U"Z>YO+*.6=\;G)/.!CUK3M+:&SMH[>V01PQC:JCL*EHH
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LAFBDZ$@Y!K"\/_#?PEX>U2+4=&T6"TO8@0DL;-D C![^AKKZ*0@HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
